| 9.3911 -0.479 (-4.85%) | 05-14 15:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.25 |
1-year : | 13.31 |
| Resists | First : | 10.49 |
Second : | 11.39 |
| Pivot price | 10.11 |
|||
| Supports | First : | 9.02 | Second : | 7.51 |
| MAs | MA(5) : | 9.72 |
MA(20) : | 10.25 |
| MA(100) : | 11.78 |
MA(250) : | 9.93  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 25 |
D(3) : | 21 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 14.51 | Low : | 6.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARVN ] has closed above bottom band by 5.4%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.08 - 10.15 | 10.15 - 10.21 |
| Low: | 9.41 - 9.49 | 9.49 - 9.57 |
| Close: | 9.74 - 9.87 | 9.87 - 9.99 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Thu, 14 May 2026
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Thu, 14 May 2026
Vanguard Group Inc. Sells 1,331,629 Shares of Arvinas, Inc. $ARVN - MarketBeat
Wed, 13 May 2026
Wall Street Analysts Think Arvinas (ARVN) Could Surge 25.57%: Read This Before Placing a Bet - MSN
Wed, 13 May 2026
Randy Teel Sells 9,657 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Wed, 13 May 2026
Arvinas (ARVN) VP Loomis has 1,919 shares sold to cover RSU taxes - Stock Titan
Wed, 13 May 2026
Arvinas (ARVN) CSO share sale covers RSU tax withholding - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 81.3 (%) |
| Shares Short | 4,390 (K) |
| Shares Short P.Month | 4,790 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.82 |
| Profit Margin | -30.8 % |
| Operating Margin | -754.8 % |
| Return on Assets (ttm) | -8 % |
| Return on Equity (ttm) | -16.3 % |
| Qtrly Rev. Growth | -84 % |
| Gross Profit (p.s.) | 4.1 |
| Sales Per Share | 4.1 |
| EBITDA (p.s.) | -1.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -274 (M) |
| Levered Free Cash Flow | -89 (M) |
| PE Ratio | -8.28 |
| PEG Ratio | 0 |
| Price to Book value | 1.38 |
| Price to Sales | 2.29 |
| Price to Cash Flow | -2.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|